Mogamulizumab for the treatment of cutaneous T-cell lymphoma: recent advances and clinical potential
Open Access
- 17 March 2016
- journal article
- review article
- Published by SAGE Publications in Therapeutic Advances in Hematology
- Vol. 7 (3), 171-174
- https://doi.org/10.1177/2040620716636541
Abstract
Mogamulizumab (KW-0761) is a humanized immunoglobulin G1 (IgG1) monoclonal antibody (mAb) that targets CC chemokine receptor 4 (CCR4). It has shown promising therapeutic potential in phase I and II clinical trials and is currently being investigated for efficacy in treating cutaneous T-cell lymphoma (CTCL). We review the mechanism of action of mogamulizumab and its role in treating CTCL. We also discuss the results of major clinical trials.Keywords
This publication has 19 references indexed in Scilit:
- CCR4 is expressed on infiltrating cells in lesional skin of early mycosis fungoides and atopic dermatitisThe Journal of Dermatology, 2015
- Reduction of Regulatory T Cells by Mogamulizumab, a Defucosylated Anti-CC Chemokine Receptor 4 Antibody, in Patients with Aggressive/Refractory Mycosis Fungoides and Sézary SyndromeClinical Cancer Research, 2015
- Loss of CCR4 antigen expression after mogamulizumab therapy in a case of adult T‐cell leukaemia‐lymphomaBritish Journal of Haematology, 2013
- Loss of CD20 antigen expression after rituximab therapy of CD20 positive B cell lymphoma (diffuse large B cell extranodal marginal zone lymphoma combination): A case report and review of the literatureMedical Oncology, 2011
- Defucosylated Humanized Anti-CCR4 Monoclonal Antibody KW-0761 as a Novel Immunotherapeutic Agent for Adult T-cell Leukemia/LymphomaClinical Cancer Research, 2010
- Overall survival in erythrodermic cutaneous T‐cell lymphoma: an analysis of prognostic factors in a cohort of patients with erythrodermic cutaneous T‐cell lymphomaInternational Journal of Dermatology, 2009
- Defucosylated anti-CCR4 monoclonal antibody exercises potent ADCC-mediated antitumor effect in the novel tumor-bearing humanized NOD/Shi-scid, IL-2Rγnull mouse modelCancer Immunology, Immunotherapy, 2008
- Th1, Th2, and activated T-cell marker and clinical prognosis in peripheral T-cell lymphoma, unspecified: comparison with AILD, ALCL, lymphoblastic lymphoma, and ATLLBlood, 2004
- Clinical significance of CCR4 expression in adult T-cell leukemia/lymphoma: its close association with skin involvement and unfavorable outcome.2003
- The Absence of Fucose but Not the Presence of Galactose or Bisecting N-Acetylglucosamine of Human IgG1 Complex-type Oligosaccharides Shows the Critical Role of Enhancing Antibody-dependent Cellular CytotoxicityPublished by Elsevier BV ,2003